Oral olanzapine

DRUG3 trials

Sponsors

Eli Lilly and Company, Teva Branded Pharmaceutical Products R&D LLC

Conditions

Bipolar DisorderSchizoaffective DisorderSchizophreniaSchizophrenic Disorders

Phase 1

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

CompletedNCT06315283

Teva Branded Pharmaceutical Products R&D LLCSchizophrenia

Start: 2024-03-20End: 2025-09-04Updated: 2026-01-14

Phase 3

Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

CompletedNCT00088491

Eli Lilly and CompanySchizophrenic Disorders

Start: 2004-06-30End: 2006-10-31Updated: 2007-06-22

Phase 4

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

CompletedNCT00303602

Eli Lilly and CompanyBipolar Disorder, Schizoaffective Disorder, Schizophrenia

Start: 2006-03-31End: 2007-12-31Updated: 2009-06-10

Related Papers

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.

2014-01-1411 citations

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.

2013-09-169 citations

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis.

2012-08-313 citations

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.

2011-02-1512 citations

The potential role of appetite in predicting weight changes during treatment with olanzapine.

2010-09-1419 citations

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.

2010-06-1075 citations

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.

2010-06-1060 citations